Pay in 4 interest-free payments of $5.27 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
When you start our program, the first step is a free assessment quiz
Comparing Weight Loss Results The head-to-head SURMOUNT-5 study shows that the dual-hormone treatment approach helped in reducing 20% of body weight compared to the single-hormone treatment that led to 15% weight loss
The key findings provide the most reliable timeline for expected results: Week 4: Average weight loss of approximately 1 to 2% of body weight Week 12: Average weight loss of approximately 5 to 6% of body weight Week 20: Average weight loss of approximately 10% of body weight Week 40: Average weight loss of approximately 13 to 14% of body weight Week 68: Average weight loss of approximately 15 to 17% of body weight These are averages, meaning some participants lost more and some lost less
Novo Nordisk provides patient assistance for those who qualify
Since tirzepatide typically produces greater weight loss (20-25% body weight versus 15-17% with semaglutide at weight loss doses), more tirzepatide users may experience telogen effluvium simply because they lost more weight faster
Potential concerns include appetite stimulation, which may counteract weight-loss goals, and ghrelin-mediated effects on cortisol and sleep
US$ 25.78
US$ 22.53
US$ 22.45
US$ 23.02
US$ 21.17
US$ 20.26
US$ 29.88
US$ 20.13
